ClinicalTrials.gg
RecruitingNCT07721649VACC-UPUpdated Oct 13, 2026

Intrahospital Influenza Vaccination in Patients at High Cardiovascular Risk (VACC-UP)

An interventional study of Intrahospital seasonal influenza vaccination offer and Standardized active influenza vaccination counseling in Acute Coronary Syndrome, Heart Failure and Influenza, Human, sponsored by Stephan Baldus. Recruiting at 2 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Stephan Baldus · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 1 month later.
Updated Oct 13, 2026Now RecruitingSite recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
482
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 92 studies in Acute Coronary Syndrome with a site in Germany — 8 open to participants now, 13 under way, 1 of them phase 3. Acute Coronary Syndrome · Germany.

Planned enrollment
40th of 59
482 · median 1,861
Started
2026
with 1 other
No phase
15 of 92
4 open now
Primary completion
2028-03
later than 10 of 12 live
Registered
92nd of 92
by date

Among the 92 studies in Acute Coronary Syndrome with a site in Germany, this one is the 40th largest by planned enrollment of the 59 interventional ones that give a count, is one of 2 that started in 2026, is one of 15 with no phase, reaches primary completion later than 10 of the 12 other live ones, and was the 92nd registered.

Acute Coronary Syndrome

1,491 studies on the registry are indexed under Acute Coronary Syndrome; 272 are open to participants now.

Browse Acute Coronary Syndrome studies →

Open to participants now

8 of the 92 studies in Acute Coronary Syndrome with a site in Germany are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 195 Acute Coronary Syndrome studies recruiting now, 144 (74%) set no upper age limit and 19 (10%) stop at 75 or younger; 15 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 92 studies in Acute Coronary Syndrome with a site in Germany, or all of them as a file.
02

Study summary

The aim of this study is to evaluate the effect of offering intrahospital influenza vaccination as an adjunct to active counseling during the index hospitalization to adult patients hospitalized for acute coronary syndrome (ACS) or congestive heart failure (CHF), compared with active counseling alone, on influenza vaccination rates in patients at high cardiovascular risk.

Patients are randomized 1:1 to either an offer of bedside intrahospital influenza vaccination according to the recommendations of the German Standing Vaccination Committee (STIKO) in addition to standardized active counseling (intervention group), or standardized active counseling plus the standard-of-care recommendation for ambulatory vaccination in the discharge papers (control group). The primary endpoint is the influenza vaccination rate at the end of the index season (March 31).

03

Conditions studied

  • Acute Coronary Syndrome
  • Heart Failure
  • Influenza, Human
  • Cardiovascular Diseases
  • Vaccination Refusal

Keywords

  • Influenza vaccination
  • Vaccination rate
  • Intrahospital vaccination
  • Acute coronary syndrome
  • Congestive heart failure
  • Health services research
  • Vaccine hesitancy
  • 7C psychological antecedents of vaccination
  • Cardiovascular prevention
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or older
  • Hospitalized due to acute coronary syndrome (ACS) or congestive heart failure (CHF) and fulfilling the criteria for influenza vaccination according to the recommendations of the German Standing Vaccination Committee (STIKO)
  • Written

Exclusion criteria

Exclusion Criteria:

  • Already received seasonal influenza vaccination in the current season, based on self-reported vaccination status and/or vaccination certificate
  • Laboratory-confirmed active influenza infection during the index hospitalization
  • for vaccination (e.g., known allergy)
  • Inability to provide written
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
482 participants (estimated)

Study arms

  • Experimental
    Intrahospital vaccination offer

    Patients receive standardized active influenza vaccination counseling and are additionally offered bedside intrahospital vaccination against seasonal influenza according to the latest STIKO recommendations at any time prior to discharge during the index hospitalization.

    Biological: Intrahospital seasonal influenza vaccination offer · Behavioral: Standardized active influenza vaccination counseling

  • Active comparator
    Active counseling alone (standard of care)

    Patients receive standardized active influenza vaccination counseling and the current standard of care in Germany, i.e., the recommendation to obtain ambulatory influenza vaccination as stated in the discharge papers. No intrahospital influenza vaccination is administered during the index hospitalization.

    Behavioral: Standardized active influenza vaccination counseling · Behavioral: Standard of care discharge recommendation for ambulatory vaccination

Interventions

  • BiologicalIntrahospital seasonal influenza vaccination offer

    Offer of bedside vaccination against seasonal influenza during the index hospitalization, administered in a standardized manner by trained treating physicians according to the latest STIKO recommendations and the respective product information. The appropriate vaccine is selected according to current recommendations (e.g., high-dose quadrivalent vaccine for patients aged 60 years and older, standard-dose quadrivalent vaccine otherwise). Vaccination is offered from September 1 to February 28 of the respective influenza season.

    Also known as: Seasonal influenza vaccine (high-dose or standard-dose according to STIKO recommendations)

  • BehavioralStandardized active influenza vaccination counseling

    Standardized active counseling on influenza vaccination using a cardiovascular gain-framed information sheet, including the recommendation to be vaccinated and the opportunity to discuss vaccination with the treating physician. Counseling is provided to all patients in both arms after completion of the baseline 7C questionnaire and prior to randomization.

  • BehavioralStandard of care discharge recommendation for ambulatory vaccination

    Current standard of care in Germany: the recommendation to obtain ambulatory influenza vaccination from the primary care physician, stated in the discharge papers.

06

What researchers measure

Primary outcomes

  1. Influenza vaccination rate at the end of the index influenza season

    Proportion of patients vaccinated against seasonal influenza at the end of the index season (defined as March 31). For intervention group patients vaccinated during the index hospitalization, vaccination status is documented from inpatient medical records. For control group patients and intervention group patients who declined intrahospital vaccination, self-reported vaccination status is assessed by telephone interview beginning April 1 and cross-validated with data from the treating general practitioner.

    Time frame: From randomization to the end of the index influenza season (March 31), up to approximately 7 months

Secondary outcomes

  1. Influenza vaccination rate at the end of the post-index influenza season

    Proportion of patients vaccinated against seasonal influenza at the end of the post-index season. For all patients, self-reported vaccination status is assessed by telephone interview beginning April 1 of the post-index season and cross-validated with data from the treating general practitioner.

    Time frame: From randomization to the end of the post-index influenza season (March 31 of the following year), up to approximately 19 months

  2. Association of the individual components of the 7C psychological antecedents of vaccination questionnaire with vaccination status

    Association of the individual components of the 7C psychological antecedents of vaccination questionnaire (7-point scale, long version), assessed at baseline prior to active counseling, with vaccination status at the end of the index season. Assessed using univariate and multivariable regression models reporting odds ratios with 95% confidence intervals.

    Time frame: Baseline (prior to counseling and randomization) and end of the index influenza season (March 31), up to approximately 7 months

  3. Patient satisfaction with the offer of intrahospital influenza vaccination

    Descriptive assessment of patient satisfaction with the intrahospital vaccination offer, based on a study-specific patient satisfaction questionnaire completed by patients in the intervention group.

    Time frame: During the index hospitalization, up to approximately 14 days

07

Study locations

2 of 2 sites recruiting
  • Clinic III for Internal Medicine, University Hospital of Cologne
    Cologne, 50937, Germany
    Recruiting
    • Sebastian Heyne, Dr. med. · Contactsebastian.heyne@uk-koeln.de · +49 221 478-82019
    • Stephan Baldus, Prof. Dr. med. · Principal investigator
  • Department of Cardiology, University Heart and Vascular Centre Hamburg
    Hamburg, 20246, Germany
    Recruiting
    • Natalie Arnold, Dr. med. · Principal investigator
08

References and documents

Publications

  • Frobert O, Gotberg M, Erlinge D, Akhtar Z, Christiansen EH, MacIntyre CR, Oldroyd KG, Motovska Z, Erglis A, Moer R, Hlinomaz O, Jakobsen L, Engstrom T, Jensen LO, Fallesen CO, Jensen SE, Angeras O, Calais F, Karegren A, Lauermann J, Mokhtari A, Nilsson J, Persson J, Stalby P, Islam AKMM, Rahman A, Malik F, Choudhury S, Collier T, Pocock SJ, Pernow J. Influenza Vaccination After Myocardial Infarction: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial. Circulation. 2021 Nov 2;144(18):1476-1484. doi: 10.1161/CIRCULATIONAHA.121.057042. Epub 2021 Aug 30. PubMed 34459211 ↗
  • Lawrence DS, Muthoga C, Meya DB, Tugume L, Williams D, Rajasingham R, Boulware DR, Mwandumba HC, Moyo M, Dziwani EN, Maheswaran H, Kanyama C, Hosseinipour MC, Chawinga C, Meintjes G, Schutz C, Comins K, Bango F, Muzoora C, Jjunju S, Nuwagira E, Mosepele M, Leeme T, Ndhlovu CE, Hlupeni A, Shamu S, Boyer-Chammard T, Molloy SF, Youssouf N, Chen T, Shiri T, Jaffar S, Harrison TS, Jarvis JN, Niessen LW; AMBITION Study Group. Cost-effectiveness of single, high-dose, liposomal amphotericin regimen for HIV-associated cryptococcal meningitis in five countries in sub-Saharan Africa: an economic analysis of the AMBITION-cm trial. Lancet Glob Health. 2022 Dec;10(12):e1845-e1854. doi: 10.1016/S2214-109X(22)00450-8. PubMed 36400090 ↗
  • Betsch C, Schmid P, Heinemeier D, Korn L, Holtmann C, Bohm R. Beyond confidence: Development of a measure assessing the 5C psychological antecedents of vaccination. PLoS One. 2018 Dec 7;13(12):e0208601. doi: 10.1371/journal.pone.0208601. eCollection 2018. PubMed 30532274 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Mar 2028, 18 months after the start.

Of 213 non-industry interventional studies with no phase under Acute Coronary Syndrome, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 46. This study's planned 18 months is below that.

Counting every sponsor, half of 228 studies reached it within 34 months; a quarter within 17 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 18, 2026
First posted
Jul 23, 2026
StartActual
Sep 30, 2026
Primary completionEst.
Mar 2028
CompletionEst.
Jun 2029
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 13, 2026
Sites
2 sites changed recruiting status (2 now recruiting)
Show 2 sites
  • Clinic III for Internal Medicine, University Hospital of Cologne · Cologne, Germanyno status→Recruiting
  • Department of Cardiology, University Heart and Vascular Centre Hamburg · Hamburg, Germanyno status→Recruiting
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Not yet recruiting→Recruiting
    2 sites changed recruiting status (2 now recruiting)
    Show 2 sites
    • Clinic III for Internal Medicine, University Hospital of Cologne · Cologne, Germanyno status→Recruiting
    • Department of Cardiology, University Heart and Vascular Centre Hamburg · Hamburg, Germanyno status→Recruiting
    + 2 other changes: verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07721649
Lead sponsor
Stephan Baldus
Collaborators
Sanofi
Responsible party
Stephan Baldus (Principal Investigator, Director of Clinic III for Internal Medicine, University Hospital of Cologne) — Sponsor-investigator
First posted
Jul 23, 2026
Start date
Sep 30, 2026
Primary completion
Mar 2028 (estimated)
Completion
Jun 2029 (estimated)
Last update
Oct 13, 2026

Study contacts

Sebastian Heyne, Dr. med.
Contact
sebastian.heyne@uk-koeln.de
+49 221 478-82019
Stephan Baldus, Prof. Dr. med.
Contact
stephan.baldus@uk-koeln.de
+49 221 478-32511
Stephan Baldus, Prof. Dr. med.
principal investigator · Clinic III for Internal Medicine, University Hospital of Cologne
Sebastian Heyne, Dr. med.
study director · Clinic III for Internal Medicine, University Hospital of Cologne

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion